3.66
+0.13(+3.68%)
Currency In USD
| Previous Close | 3.53 |
| Open | 3.56 |
| Day High | 3.86 |
| Day Low | 3.56 |
| 52-Week High | 4.14 |
| 52-Week Low | 2.46 |
| Volume | 720,438 |
| Average Volume | 398,996 |
| Market Cap | 290.45M |
| PE | -2.26 |
| EPS | -1.62 |
| Moving Average 50 Days | 3.52 |
| Moving Average 200 Days | 3.19 |
| Change | 0.13 |
If you invested $1000 in Atea Pharmaceuticals, Inc. (AVIR) since IPO date, it would be worth $120.63 as of August 23, 2025 at a share price of $3.66. Whereas If you bought $1000 worth of Atea Pharmaceuticals, Inc. (AVIR) shares 3 years ago, it would be worth $452.97 as of August 23, 2025 at a share price of $3.66.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Atea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update Conference Call on August 7, 2025
GlobeNewswire Inc.
Jul 31, 2025 11:00 AM GMT
BOSTON, July 31, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, to
Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America
GlobeNewswire Inc.
Jun 24, 2025 11:00 AM GMT
C-FORWARD is the Second Phase 3 Trial in the Global HCV Development Program; the First Phase 3 Trial, C-BEYOND, is Currently Enrolling Patients in the US and Canada Regimen has Potential Best-in-Class Profile with Short Treatment Duration, Low Risk f
Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025
GlobeNewswire Inc.
May 07, 2025 11:00 AM GMT
Full Results from Phase 2 Study Confirmed 98% Sustained Virologic Response at 12 Weeks Post-Treatment (SVR12) After Short 8-Week Treatment Duration for Regimen Results from Phase 1 Study Showed Low Risk for Drug-Drug Interactions with Regimen